Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00145210 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Nebivolol in the Treatment of Hypertension in African Americans
A Phase 3 study, sponsored by Mylan Bertek Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 630
- Enrollment target
NCT00145210: Completed Phase 3 study, sponsored by Mylan Bertek Pharmaceuticals.
NCT00145210 is a Phase 3 study that has completed, run by Mylan Bertek Pharmaceuticals. The registered enrollment target is 630 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00145210, a Phase 3 study, has completed, sponsored by Mylan Bertek Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 630 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effects of nebivolol on blood pressure and heart rate in African American patients with hypertension.
Interventions
- DRUG Nebivolol and Atenolol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 630 participants |
| Start Date | 2005-04 |
| Est. Completion | 2007-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00145210
The ClinicalTrials.gov registry entry for NCT00145210 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 630 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mylan Bertek Pharmaceuticals, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Nebivolol and Atenolol is the first listed.
NCT00145210 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00145210 about?
NCT00145210 is a clinical study titled "Safety and Efficacy of Nebivolol in the Treatment of Hypertension in African Americans". The purpose of this study is to evaluate the effects of nebivolol on blood pressure and heart rate in African American patients with hypertension.
What is the current status of trial NCT00145210?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 630 participants. The study started on 2005-04. Estimated completion is 2007-09.
What interventions are being tested in trial NCT00145210?
The interventions under investigation include: Nebivolol and Atenolol (DRUG).
Who is sponsoring clinical trial NCT00145210?
This trial is sponsored by Mylan Bertek Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.